Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

32.04 -0.36 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,224
Open 32.00
Bid (Size) 31.61 (100)
Ask (Size) 32.70 (4,100)
Prev. Close 32.40
Today's Range 30.93 - 32.70
52wk Range 17.00 - 48.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
 
Via Benzinga

Performance

YTD
+85.7%
+85.7%
1 Month
-12.1%
-12.1%
3 Month
-20.0%
-20.0%
6 Month
+32.4%
+32.4%
1 Year
+85.7%
+85.7%

More News

Read More
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
Via Benzinga
Earnings Scheduled For August 20, 2025
Via Benzinga
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns'
Via Benzinga
Topics Artificial Intelligence Government
Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Via Benzinga
Topics Artificial Intelligence
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
Via Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Via Benzinga
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Earnings Scheduled For March 27, 2025
Via Benzinga
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains
Via Benzinga
Topics Initial Public Offering
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire

Frequently Asked Questions

Is Ascentage Pharma Group International - American Depository Shares publicly traded?
Yes, Ascentage Pharma Group International - American Depository Shares is publicly traded.
What exchange does Ascentage Pharma Group International - American Depository Shares trade on?
Ascentage Pharma Group International - American Depository Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Ascentage Pharma Group International - American Depository Shares?
The ticker symbol for Ascentage Pharma Group International - American Depository Shares is AAPG on the Nasdaq Stock Market
What is the current price of Ascentage Pharma Group International - American Depository Shares?
The current price of Ascentage Pharma Group International - American Depository Shares is 32.04
When was Ascentage Pharma Group International - American Depository Shares last traded?
The last trade of Ascentage Pharma Group International - American Depository Shares was at 11/11/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.